CARINGFORTHE
CRITICALLYILLPATIENT
Transfusion Requirements
After Cardiac Surgery
The TRACS Randomized Controlled Trial
LudhmilaA.Hajjar, MD,PhD
Context Perioperativeredbloodcelltransfusioniscommonlyusedtoaddressane-
Jean-LouisVincent, MD,PhD mia,anindependentriskfactorformorbidityandmortalityaftercardiacoperations;
however,evidenceregardingoptimalbloodtransfusionpracticeinpatientsundergo-
FilomenaR.B.G.Galas, MD,PhD
ingcardiacsurgeryislacking.
RosanaE.Nakamura, MD
Objective To define whether a restrictive perioperative red blood cell transfusion
CarolinaM.P.Silva, MD strategyisassafeasaliberalstrategyinpatientsundergoingelectivecardiacsurgery.
MariliaH.Santos, MD,PhD Design,Setting,andPatients TheTransfusionRequirementsAfterCardiacSur-
JuliaFukushima, MSc gery(TRACS)study,aprospective,randomized,controlledclinicalnoninferioritytrial
conductedbetweenFebruary2009andFebruary2010inanintensivecareunitata
RobertoKalilFilho, MD,PhD
universityhospitalcardiacsurgeryreferralcenterinBrazil.Consecutiveadultpatients
DeniseB.Sierra, MD (n=502)whounderwentcardiacsurgerywithcardiopulmonarybypasswereeligible;
analysiswasbyintention-to-treat.
NeuzaH.Lopes, MD,PhD
Intervention Patientswererandomlyassignedtoaliberalstrategyofbloodtrans-
ThaisMauad, MD,PhD
fusion(tomaintainahematocrit(cid:2)30%)ortoarestrictivestrategy(hematocrit(cid:2)24%).
AretusaC.Roquim, MD
MainOutcomeMeasure Compositeendpointof30-dayall-causemortalityand
MarciaR.Sundin, MD severemorbidity(cardiogenicshock,acuterespiratorydistresssyndrome,oracutere-
WandersonC.Lea˜o, MD nalinjuryrequiringdialysisorhemofiltration)occurringduringthehospitalstay.The
noninferioritymarginwaspredefinedat−8%(ie,8%minimalclinicallyimportantin-
JulianoP.Almeida, MD
creaseinoccurrenceofthecompositeendpoint).
PabloM.Pomerantzeff, MD,PhD
Results Hemoglobinconcentrationsweremaintainedatameanof10.5g/dL(95%con-
LuisO.Dallan, MD,PhD fidenceinterval[CI],10.4-10.6)intheliberal-strategygroupand9.1g/dL(95%CI,9.0-
9.2)intherestrictive-strategygroup(P(cid:3).001).Atotalof198of253patients(78%)in
FabioB.Jatene, MD,PhD
theliberal-strategygroupand118of249(47%)intherestrictive-strategygroupreceived
NoedirA.G.Stolf, MD,PhD abloodtransfusion(P(cid:3).001).Occurrenceoftheprimaryendpointwassimilarbetween
groups(10%liberalvs11%restrictive;between-groupdifference,1%[95%CI,−6%to
JoseO.C.AulerJr, MD,PhD
4%];P=.85).Independentoftransfusionstrategy,thenumberoftransfusedredblood
C
ARDIACSURGERYISASSOCIATED cellunitswasanindependentriskfactorforclinicalcomplicationsordeathat30days(haz-
withahighrateofallogeneic ardratioforeachadditionalunittransfused,1.2[95%CI,1.1-1.4];P=.002).
bloodtransfusion,varyingfrom Conclusion Amongpatientsundergoingcardiacsurgery,theuseofarestrictiveperi-
40%to90%inmostreports.1-3 operativetransfusionstrategycomparedwithamoreliberalstrategyresultedinnoninfe-
Therationaleforperioperativeredblood riorratesofthecombinedoutcomeof30-dayall-causemortalityandseveremorbidity.
cell(RBC)transfusionisbasedontheob- TrialRegistration clinicaltrials.govIdentifier:NCT01021631
servationthatanemiaisanindependent
JAMA.2010;304(14):1559-1567 www.jama.com
riskfactorformorbidityandmortalityaf-
tercardiacoperations.4,5However,trans- diac,andneurologiccomplications,in Thereisalackofevidenceregarding
fusionshavebeenassociatedwithhigh transfusedcomparedwithnontransfused optimalbloodtransfusionpracticeinpa-
ratesofmorbidityandmortalityincriti- patientsaftercardiacsurgery.7,8 tientsundergoingcardiacsurgery.9On
callyillpatients,6andsomerecentstud-
ieshaveshownworseoutcomes,includ- AuthorAffiliations:SurgicalIntensiveCareUnitand site´LibredeBruxelles,Brussels,Belgium(DrVincent).
DepartmentofAnesthesiology,HeartInstitute(InCor), CorrespondingAuthor:Jean-LouisVincent,MD,PhD,
ingincreasedoccurrenceofrenalfailure
Hospital das Clinicas da Faculdade de Medicina da DepartmentofIntensiveCare,ErasmeUniversityHos-
andinfection,aswellasrespiratory,car- UniversidadedeSa˜oPaulo,Sa˜oPaulo,Brazil(DrsHajjar, pital,RoutedeLennik808,B-1070Brussels,Belgium
Galas,Nakamura,Silva,Santos,KalilFilho,Sierra,Lopes, (jlvincen@ulb.ac.be).
Mauad,Roquim,Sundin,Lea˜o,Almeida,Pomerantzeff, CaringfortheCriticallyIllPatientSectionEditor:Derek
Seealsopp1568and1610. Dallan,Jatene,Stolf,andAulerandMsFukushima);and C.Angus,MD,MPH,ContributingEditor,JAMA
DepartmentofIntensiveCare,ErasmeHospital,Univer- (angusdc@upmc.edu).
©2010AmericanMedicalAssociation.Allrightsreserved. (Reprinted)JAMA,October13,2010—Vol304,No.14 1559
Downloaded From: http://jama.jamanetwork.com/ by a SUNY Binghamton User on 05/13/2015
TRANSFUSIONREQUIREMENTSAFTERCARDIACSURGERY
the basis of past clinical observations, scendingthoracicaorticprocedures;left egy). Hematocrit levels were mea-
someauthorshavesuggestedthathemat- ventricularaneurysmresection;inabil- suredatleast3timesintheoperating
ocritshouldbemaintainedataround30% itytoreceivebloodproducts;enrollment room and twice daily in the ICU for
and hemoglobin concentration at 10 inanotherstudy;chronicanemia(pre- each patient. Attending physicians
g/dL.10Recently,however,thishemoglo- operativehemoglobinconcentrationless couldadministerRBCtransfusionsout-
binthresholdhasbeenreconsideredbe- than10g/dL);lowplateletcount(pre- sidetherulesoftheprotocoliftheycon-
causeofrecognizedrisksassociatedwith operative platelet count less than 150 sidered the patient’s status to be life-
transfusionandgreaterappreciationof (cid:4)103/µL);coagulopathy(previoushis- threatening,asinhemorrhagicorother
theimportanceofindividualphysiologi- toryorprothrombintimelongerthan14.8 forms of circulatory shock; such an
calresponsestoanemia.11Inacompara- seconds);pregnancy;neoplasm;endocar- eventwasconsideredaprotocoldevia-
tivetrialof428patientsundergoingelec- ditis;congenitalheartdefect;hepaticdys- tion. Patients were analyzed in their
tivecoronaryarterybypassgraft(CABG) function(totalbilirubinvaluehigherthan originallyassignedgroupsonaninten-
surgery,Braceyetalreportedthatreduc- 1.5mg/dL[toconverttoµmol/L,multi- tion-to-treatbasis.
ingthehemoglobintriggerto8g/dLdid plyby17.104]);end-stagerenaldisease AttheHeartInstitute,RBCsaresepa-
notadverselyaffectpatientoutcomesand (receivingchronicdialysistherapy);and ratedfromwholebloodandstoredina
resultedinlowercosts.12 refusaltoconsent. citratesolutionwithoutleukodepletion.
AnimportantmulticenterCanadian ThestudywasapprovedbytheHeart ThevolumeofanRBCunitrangesfrom
studybyHe´bertetalthatincludedalarge InstituteEthicsCommittee,ClinicsHos- 250to350mL,withahematocritof80%.
numberofcriticallyillpatients(butnot pital,UniversityofSa˜oPaulo,andwrit- Inourhospital,bloodbankpolicyisto
thoseundergoingcardiacsurgicalproce- teninformedconsentwasobtainedfrom usebloodwithshort-durationstoragein
dures)revealedthatarestrictivetransfu- allpatientsbeforeenrollment. patientsundergoingcardiacsurgery.
sionstrategy(hemoglobinconcentration Patientswererandomlyassignedtoa
maintainedbetween7.0and9.0g/dL)may liberalorarestrictivetransfusionstrat- SurgicalProcedureandICUAdmission
besuperiortoaliberalstrategy(hemoglo- egy.Opaqueenvelopesarrangedusing Preoperative medication consisted of
bin concentration between 10 and 12 arandom-numbertablewereprepared midazolam(0.1to0.2mg/kggivenorally
g/dL)intermsofreducingorgandysfunc- bythechiefstatisticianandopenedse- 30minutesbeforesurgery).Anesthesia
tionandmortality.13Therecurrentlyare quentially to determine the patient’s wasinducedwithfentanyl(3-5µg/kg),
nodatafromprospectiverandomizedtrials treatmentgroup.Theresearchcoordi- midazolam(0.05mg/kg),etomidate(0.2-
toguidetransfusiondecisionsinpatients natorenrolledtheparticipantsandob- 0.3mg/kg),andpancuroniumbromide
undergoingcardiacsurgery.Wetherefore tained informed consent. Information (0.1 mg/kg). Anesthesia was main-
conductedtheTransfusionRequirements aboutthetreatmentstrategywasgiven tainedwithisofluraneinoxygenandfen-
AfterCardiacSurgery(TRACS)study,a totheanesthesiologistandtohealthcare tanylasneeded.Duringcardiopulmo-
prospective,randomized,controlledclini- workersintheintensivecareunit(ICU). nary bypass, additional doses of
caltrialtoelucidatewhetherarestrictive Thepatientandoutcomeassessorswere midazolamandpancuroniumweread-
perioperativestrategyofRBCtransfusion blindedtogroupassignment. ministeredasrequired.Allpatientswere
wasassafeasaliberalstrategyinpatients Transfusion triggers for the study monitoredwithanarterialandcentral
undergoingelectivecardiacsurgery. groupsweredeterminedfrominforma- venous catheter; some also received a
tionobtainedfrompreviousstudiesthat pulmonary artery catheter. After tra-
METHODS
showedthathematocritvaluesaslowas chealintubation,allpatientsreceivedin-
StudyDesignandTreatmentStrategies 22%aresafeincardiacsurgerywithcar- vasivemechanicalventilationwithin-
The TRACS study was designed as a diopulmonary bypass.14,15 Patients as- termittentpositivepressurewithatidal
prospective,randomized,noninferiority signedtotheliberal-strategygroupre- volume of 8 mL/kg, positive end-
controlled trial. Consecutive patients ceivedRBCtransfusionsifthehematocrit expiratorypressureof5to8cmHO,and
2
scheduledforelectivecardiacsurgerywith waslessthan30%atanytimefromthe fractionofinspiredoxygenof0.6to1to
cardiopulmonarybypassattheHeartIn- startofsurgeryuntildischargefromthe keep arterial oxygen saturation above
stituteoftheUniversityofSa˜oPaulo,Sa˜o ICU.Patientsassignedtotherestrictive- 95%. Nitroglycerin and sodium nitro-
Paulo,Brazil,betweenFebruary9,2009, strategygroupreceivedRBCtransfusions prusside were administered intrave-
andFebruary1,2010,wereenrolled.We ifhematocritvalueswerelessthan24%. nouslyasvasodilators,dobutamineasan
includedpatientswhowereundergoing Physicianswereinstructedtoadmin- inotrope,andnorepinephrineandepi-
CABGsurgeryorcardiacvalvereplace- istertransfusionsoneunitatatimeand nephrine as vasopressors. In all pa-
mentorrepair,aloneorincombination. tomeasurehematocritaftereachtrans- tients,bloodglucoselevelswerekeptbe-
Patientswereexcludedforanyofthefol- fusedunit.Inbothgroups,nofurther low160mg/dL(toconverttommol/L,
lowingreasons:youngerthan18years; unitsweregivenifthegoalhematocrit multiplyby0.0555),usingcontinuous
surgerywithoutcardiopulmonarybypass; was obtained (24% for the restrictive intravenousinsulinifneeded.Methyl-
emergencyprocedure;ascendingandde- strategyand30%fortheliberalstrat- prednisolone(10mg/kg)andcefurox-
1560 JAMA,October13,2010—Vol304,No.14(Reprinted) ©2010AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a SUNY Binghamton User on 05/13/2015
TRANSFUSIONREQUIREMENTSAFTERCARDIACSURGERY
ime(750mg)wereadministeredintra- ment was accomplished with lactated patientsinthecardiacICU.Hemoglo-
venouslyatinductionofanesthesia.All Ringersolutionandadjustedaccording binandhematocritweremeasuredev-
surgical procedures were undertaken to filling pressures, diuresis, and car- ery12hoursuntilICUdischarge.Lev-
throughamediansternotomy. diacoutput.Albuminorhydroxyethyl elsofserumcreatinine,creatinekinase
Inallpatients,clopidogrelandoral starch(130/0.4)couldbeadministered MB, troponin, electrolytes, lactate,
anticoagulantswerestoppedatleast5 ifconsiderednecessary. blood gases, and bilirubin were mea-
days before surgery. All patients re- PatientsweretransferredtotheICU suredoncedaily.Clinicalandlabora-
ceived5gofε-aminocaproicacid,an beforerecoveryfromanesthesiawhile torydatafortheSimplifiedAcutePhysi-
antifibrinolytic, at induction of anes- stillreceivingmechanicalventilation. ology Score II17 and for the Acute
thesiaandanadditional1g/huntilthe Patientswereweanedfromtheventi- PhysiologyandChronicHealthEvalu-
endofsurgery.Anticoagulationwases- latorafterexhibitingcompleterecov- ationIIscore18wererecordedusingthe
tablished with an initial dose of 500 eryfromanesthesia,hemodynamicsta- worstvaluewithinthefirst24hoursaf-
IU/kgofheparininjectedintothecen- bility with no evidence of significant terICUadmission.Datawerealsore-
tralvenouslinebeforeinitiationofby- bleeding,coretemperaturehigherthan corded regarding hemodynamic sta-
pass, with a target activated clotting 36°C,andadequatebloodgasvalues. tus,needforvasoactivedrugsandother
timeof480seconds.Additionalhepa- PatientsweredischargedfromtheICU medications,needformechanicalven-
rin was given intermittently to titrate onthesecondpostoperativedayifthey tilation, need for dialysis, and other
clottingtimesduringbypass.Attheend metinstitutionaldischargecriteria. formsoforgandysfunction.Duringthe
ofbypass,heparinwasreversedbyprot- hospital stay, data were collected re-
aminechlorideina1:1ratio,withad- BaselineAssessment gardingtheuseofRBCtransfusion,he-
ditional protamine given as required andDataCollection matocritgoals,andcomplications.Af-
toreturntheactivatedclottingtimeto At the time of randomization, demo- ter discharge from the ICU, clinical
preoperativevalues.Acoagulationpro- graphicandclinicaldataaswellasthe outcomeswereevaluatedontheregu-
file and platelet count were obtained informationneededtocalculatethepre- larward,stillinablindedfashion.
after heparin reversal. Significant in- dicted risk of surgery using the stan- Respiratorycomplicationswerede-
traoperative bleeding associated with dardEuroSCORE(EuropeanSystemfor finedasprolongedneedformechani-
plateletdisordersorcoagulopathycould Cardiac Operative Risk Evaluation)16 calventilation((cid:6)48hours)anddevel-
betreatedusingplatelets,freshfrozen wereobtainedforeachpatient.Preop- opment of pneumonia or acute
plasma, or cryoprecipitate. Surgeons erativelaboratoryvalues,collectedupto respiratorydistresssyndrome(ARDS)
performedahemostasisreview.Cellsal- 48hoursbeforesurgery,wererecorded defined by standard criteria.19 Pneu-
vagewasnotused. andincludedhemoglobin,hematocrit, moniawasdiagnosedifthepatienthad
Acentrifugalpump(MedtronicBio- prothrombin time, activated partial anew,persistent,orprogressivelung
medicus; Medtronic, Minneapolis, thromboplastintime,creatininelevel,bil- infiltrateonchestradiographandifat
Minnesota)wasusedforbypass.Anex- irubinlevel,andplateletcounts. least 2 of the following criteria were
tracorporealcircuitcontainingamicro- During surgery, hemoglobin levels present:temperature38°Corgreater,
porouspolypropylenemembraneoxy- andhematocritweremeasuredatbase- leukocytosis greater than 12000
genator(Braile;Sa˜oJose´doRioPreto,Sa˜o line (just after induction of anesthe- cells/µLorleukopenialessthan3000
Paulo, Brazil) with an integrated ve- sia),duringbypass,andattheendof cells/µL,orpurulentendotrachealse-
nouscardiotomyreservoirwasused.The the procedure. Central venous oxy- cretions with a Gram stain showing
oxygenatorwasprimedwith1500mL gensaturation(SCVO2)andlactatecon- more than 25 neutrophils and fewer
oflactatedRingersolution,20%(1g/kg) centrationweremeasuredatthebegin- than10epithelialcellsperfield.20Inpa-
mannitol,and2500unitsofunfraction- ning and end of the procedure. tients receiving mechanical ventila-
atedheparin.Duringbypass,amildhy- Informationwasalsocollectedonthe tionandwithclinicalsuspicionofnoso-
pothermic temperature management typeofsurgicalprocedure,numberand comialpneumonia,bronchialsecretions
strategy(32°Cto34°C)with(cid:5)-statblood type of grafts used, duration of by- forcultureswereobtainedwithapro-
gas management was used in all pa- pass,durationofcross-clamping,num- tectedpulmonaryspecimenbrushin-
tients.Duringbypass,nonpulsatileflow berofRBCunitstransfused,adminis- troduced by fiberoptic bronchoscopy
wasmaintainedat2.0to2.4L/minper trationofotherbloodproducts,amount throughtheendotrachealtube.
square meter, and mean arterial pres- and type of fluids administered, and Cardiaccomplicationsincludedcar-
surevariedfrom60to90mmHg.Myo- clinically important events such as diogenic shock, tachyarrhythmia, or
cardialpreservationwasachievedbyin- bleedingorhemodynamicinstability. perioperative cardiac ischemia. Car-
termittent antegrade cold crystalloid During the ICU stay, clinical data diogenicshockwasdefinedasthepres-
cardioplegia. Cardioplegia was re- were collected daily by 2 blinded as- enceoftachycardia,hypotension,and
peated every 30 minutes during the sessors, both trained physicians with poorperfusionassociatedwithSCVO2
cross-clamping period. Fluid manage- morethan3years’experiencecaringfor lessthan65%ormetabolicacidosis(de-
©2010AmericanMedicalAssociation.Allrightsreserved. (Reprinted)JAMA,October13,2010—Vol304,No.14 1561
Downloaded From: http://jama.jamanetwork.com/ by a SUNY Binghamton User on 05/13/2015
TRANSFUSIONREQUIREMENTSAFTERCARDIACSURGERY
crease in base deficit (cid:6)4) or an in- filtration)occurringduringthehospi- Resultsareexpressedasmeanswith
creaseinlactatelevel((cid:6)18.02mg/dL tal stay. These clinical complications 95%confidenceintervals(CIs)orme-
[to convert to mmol/L, multiply by were selected because of the estab- dianswithinterquartileranges(IQRs).
0.111])intheabsenceofacauseother lishedassociationbetweenthesecom- Amultiplelogisticregressionanalysis
thanheartfailure.21Anelectrocardio- plications and blood transfusion and was performed to estimate predictive
gram was performed twice daily dur- their known association with mortal- factorsforprimaryandsecondaryout-
ingtheICUstayandoncedailyonthe ity.5,9,12,13 Secondary outcomes in- comes and predictive factors for red
regularward.Perioperativecardiacis- cludedallrespiratory,cardiac,neuro- bloodcelltransfusion,includingvari-
chemia was considered if creatine ki- logic, and infectious complications; ablessignificantintheunivariatemodel,
naseMBlevelwaselevatedtoatleast inflammatory complications; bleed- ie, age, sex, body mass index (calcu-
5timestheupperlimitofnormal((cid:6)30 ingrequiringreoperation;andICUand latedasweightinkilogramsdividedby
ng/mL),iftroponinIvaluesweregreater hospitallengthsofstay.Wealsoevalu- height in meters squared), comorbid
than5ng/mLduringthefirst72hours, ated the incidence of RBC transfu- conditions,leftventricularejectionfrac-
ifnewpathologicalQwavesappeared, sions and the number of units trans- tionandEuroSCORE,typeofsurgery,
ifcoronaryarteryocclusionwasangio- fused, predictive factors for RBC duration of cardiopulmonary bypass,
graphicallydocumented,oriftherewas transfusions, and the effects of trans- initialandfinalhemoglobinlevel,he-
imagingevidenceofnewlossofviable fusiononpatientoutcomes. matocrit,lactateconcentration,SCVO2,
myocardium.22 andnumberofRBCunitstransfused.
Renal function was evaluated daily StatisticalAnalysis We calculated unadjusted 30-day
usingtheRIFLE(renalrisk,injury,fail- Thiswasanoninferioritytrial,andwe Kaplan-Meiersurvivalestimates,divid-
ure,loss,end-stagekidneydisease)clas- estimateda10%incidenceofthepri- ingpatientsbytransfusionstrategyand
sification.23Theneedforrenalreplace- mary outcome.12,13 Based on previous by number of transfused RBC units,
menttherapywasrecorded. studies,12,13 we predicted there would usingalog-ranktest.Todeterminethe
Neurologiccomplicationswerediag- benodifferencebetweengroupsforthe riskofdeathat30daysaccordingtothe
nosedifthepatientpresentedwithde- primaryoutcomeeventrateandsetthe number of transfused RBC units, we
lirium (the Confusion Assessment noninferiority margin at −8% (mini- built a multivariate Cox proportional
MethodintheICUscale24wasapplied mal clinically important difference of hazard model in the overall popula-
daily)orstroke,whichwascharacter- 8%). To obtain 90% statistical power tionwithdeathasthedependentfac-
izedbyanewfocaldeficitwithacom- witha1-sided(cid:5)=.05,atleast482pa- tor,usingthevariablesabove.
patibleimageoncomputedtomography. tients needed to be enrolled. Consid- A1-sidedPvaluelessthan.05was
Infectiouscomplicationsincludedsep- ering the probability of subject attri- consideredstatisticallysignificant.Sta-
tic shock, defined by standard crite- tion,weadded6%tothesamplesize, tisticalanalyseswereperformedusing
ria25;mediastinitis,definedasasuperfi- yieldingafinalrequirednumberof512 SPSSversion18.0(SPSSInc,Chicago,
cialordeepinfectionofthesternotomy patients.Aninterimanalysiswascon- Illinois).
wound with positive findings on cul- ductedbythemonitoringcommitteeaf-
RESULTS
tures obtained from the wound; and ter250patientshadbeenenrolled,and
pneumoniaasdescribedabove.Inflam- themonitoringboardadvisedthatthe StudyPopulation
matorycomplicationswerediagnosedif trialshouldbecontinued. Atotalof1765patientswereassessed
thepatienthadvasodilatoryshock,as- We compared baseline characteris- foreligibility(FIGURE1).Afterexclu-
sociatedwithacardiacindexgreaterthan tics, follow-up measures, and clinical sionsforvariousmedicalreasonsand
4.0L/minpersquaremeter.Bleedingwas outcomesonanintention-to-treatba- lackofconsent,512patientswereen-
defined as clinically important when sisaccordingtotherandomizedstudy rolledinthestudy:257assignedtothe
bloodlossexceeded100to300mL/haf- group assignment. Continuous vari- liberaltransfusionstrategygroupand
terICUadmissionandpatientsneeded ableswerecomparedusingattestor 255totherestrictivetransfusionstrat-
reoperation.26Operativemortalitywas Mann-WhitneyUtestandcategorical egygroup.Ofthese,10patients(1.9%)
consideredasdeathfromallcausesinthe variablesusingPearson(cid:7)2orFisherex- (4 in the liberal-strategy group and 6
30daysaftersurgery.Telephonecon- act or likelihood ratio test. Logarith- intherestrictive-strategygroup)were
tactwasusedtoevaluatethisoutcome. mictransformationwasperformedto excluded after consent because sur-
normalize the distribution of vari- gerywasperformedwithoutcardiopul-
OutcomeMeasures ablessoparametrictestscouldbeused. monarybypass,leaving502(253inthe
The primary outcome was a compos- Comparisons of hemoglobin concen- liberal-strategygroupand249inthere-
iteendpointthatincluded30-dayall tration over time were made using strictive-strategy group) in the inten-
cause mortality and severe morbidity analysisofvariancewithrepeatedmea- tion-to-treat analysis. In the liberal-
(cardiogenicshock,ARDS,oracutere- sures,followedbytheleast-squaresdif- strategygroup,therewerenocasesof
nalinjuryrequiringdialysisorhemo- ferencetesttodiscriminatedifferences. protocol deviation. Four of the pa-
1562 JAMA,October13,2010—Vol304,No.14(Reprinted) ©2010AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a SUNY Binghamton User on 05/13/2015
TRANSFUSIONREQUIREMENTSAFTERCARDIACSURGERY
tientsintherestrictive-strategygroup
Figure1.StudyFlow
wereconsideredtohavedeviatedfrom
protocolbecausetheyreceived1RBC
1765Patients assessed
unitoutsidetheprotocoltriggertoad-
dresshemodynamicinstability. 1084Excluded
205Chronic anemia
Baselinecharacteristicswerewellbal-
124Enrolled in other studies
anced between the study groups 123Emergency procedure
105Surgery without bypass
(TABLE).Hemoglobinconcentrationsat 93Coagulopathy
thetimeofrandomizationweresimi- 90Aortic procedure
85Congenital heart defect
lar in the liberal- and restrictive- 82Active endocarditis
strategygroups(mean,13.1g/dL[SD, 78Low platelet count
73End-stage renal disease
1.6]vs13.4g/dL[SD,1.8],P=.18).Pro- 26Inability to receive blood
products
cedure-related variables in the intra-
operativeperiodweresimilarbetween 681Screened for consent
groups, with the exception of RBC
169Excluded (did not provide
transfusion(eTable1,availableathttp://
consent)
www.jama.com).
512Randomized
Intervention
Hemoglobinconcentrationsweresig- 257Randomized to liberal 255Randomized to restrictive
nificantly higher in the liberal- transfusion strategy transfusion strategy
strategygroupthanintherestrictive-
253Underwent intervention 249Underwent intervention
strategy group intraoperatively (final as randomized as randomized
4Did not undergo intervention 6Did not undergo intervention
hemoglobinlevel),immediatelypost- (change in surgical plan)a (change in surgical plan)a
operatively,andatdays1,2,3,and7
after ICU admission (FIGURE 2). The 0Deviated from protocol 4Deviated from protocol (received
1 RBC unit outside protocol trigger)
meanhemoglobinconcentrationswere
10.5g/dL(95%CI,10.4-10.6)inthelib- 253Included in primary analysis 249Included in primary analysis
eral-strategygroupand9.1g/dL(95%
CI,9.0-9.2)intherestrictive-strategy RBCindicatesredbloodcell.
aPatientsexcludedafterconsentbecauseofachangeinsurgicalplansuchthatsurgerywasperformedwith-
group(P(cid:3).001).Hematocritconcen-
outcardiopulmonarybypass.
trationsweremaintainedaboveoratthe
thresholdfor95%ofthetime;overall
average hematocrit values in the ICU groups(median,3[IQR,2-3]vs3[IQR, (eFigure2).Thelowerlimitofthebe-
were31.8%(95%CI,31.5%-32.1%)in 2-3]days;P=.28).Duringthehospital tween-groupdifferenceCIisabovethe
the liberal-strategy group and 28.4% stay,therewerenodifferencesbetween −8%predefinednoninferioritythresh-
(95%CI,27.9%-28.9%)intherestric- the groups in the use of fresh frozen old, confirming the primary hypoth-
tive-strategygroup(P(cid:3).001). plasma(27%[95%CI,16%-26%]vs21% esis of noninferiority between the
Asexpected,morepatientsinthelib- [95%CI,13%-22%],P=.11),platelets groups. There was no significant dif-
eral-strategy group received a blood (10%[95%CI,3%-9%]vs9%[95%CI, ference between the strategies in 30-
transfusion than in the restrictive- 4%-10%],P=.92),orcryoprecipitate(4% day mortality rates (5% [95% CI,
strategygroup(78%vs47%,P(cid:3).001). [95%CI,1%-4%]vs4%[95%CI,0%- 2%-7%] vs 6% [95% CI, 3%-9%], re-
ThetotalnumberoftransfusedRBCunits 4%],P=.97). spectively;P=.93)(FIGURE3)orrates
was613intheliberal-strategygroupand of cardiogenic shock (5% [95% CI,
258 in the restrictive-strategy group OutcomeMeasures 2%-7%] vs 9% [95% CI, 5%-12%],
(P(cid:3).001).Mosttransfusionsweregiven The primary composite end point— P=.42), ARDS (1% [95% CI, 0%-2%]
intheoperatingroomorinthefirst3 all-cause 30-day mortality, cardio- vs 2% [95% CI, 0%-4%], P=.99), or
daysaftersurgery.Theliberal-strategy genicshock,ARDS,oracuterenalin- acuterenalfailurerequiringdialysisor
groupreceivedamedianof2RBCunits juryrequiringdialysisorhemofiltration hemofiltration (5% [95% CI, 2%-9%]
(IQR, 1-3), while the restrictive- duringthehospitalstay—occurredin vs 4% [95% CI, 2%-6%], P=.99)
strategy group received a median of 0 10%(95%CI,6%-13%)ofpatientsin (eFigure2).
RBCunits(IQR,0-2)(P(cid:3).001)(eFig- theliberal-strategygroupandin11% There were no significant differ-
ure1).Therewasnodifferenceinthe (95% CI, 7%-15%) in the restrictive- encesintheoccurrenceofcardiaccom-
median storage age of RBC units be- strategygroup(between-groupdiffer- plications(21%[95%CI,16%-26%]vs
tweentheliberal-vsrestrictive-strategy ence,1%[95%CI,−6%to4%];P=.85) 24%[95%CI,18%-29%],P=.27),res-
©2010AmericanMedicalAssociation.Allrightsreserved. (Reprinted)JAMA,October13,2010—Vol304,No.14 1563
Downloaded From: http://jama.jamanetwork.com/ by a SUNY Binghamton User on 05/13/2015
TRANSFUSIONREQUIREMENTSAFTERCARDIACSURGERY
piratorycomplications(11%[95%CI, 26.13 mg/dL [95% CI, 24.32-27.93], [95% CI, 55.9-59.2]; P=.003), more
7%-14%] vs 11% [95% CI, 7%-15%], P=.49). There were also no differ- likelytobewomen(48vs22%,P(cid:3).001),
P=.82),neurologiccomplications(6% encesinlengthsofICUstay(median, and less likely to be smokers (39% vs
[95%CI,3%-9%]vs6%[95%CI,3%- 3days[IQR,2-6]vs3days[IQR,2-6]; 56%,P(cid:3).001)(eTable2).Theyhada
9%],P=.96),infectiouscomplications P=.94)orhospitalstay(median,9days lowerbodymassindex(25.8[95%CI,
(10%[95%CI,6%-14%]vs12%[95% [IQR, 7-14] vs 9 days [IQR, 7-15]; 25.3-26.3] vs 27 [95% CI, 26.3-27.6],
CI,8%-16%],P=.58),orseverebleed- P=.45). P=.004), higher EuroSCORE values
ingrequiringreoperation(4%[95%CI, (median,5[IQR,3-7]vs3[IQR,2-5];
2%-7%] vs 5% [95% CI, 2%-8%], RBCTransfusion:PredictiveFactors P(cid:3).001),lowerpreoperativehemoglo-
P=.97) (eFigure 2). During the ICU andEffectsonOutcomes bin levels (12.7 g/dL [95% CI, 12.5-
stay,therewasnodifferencebetween Intotal,316patients(63%)receivedan 12.9]vs14.2g/dL[95%CI,13.9-14.4],
between the liberal- and restrictive- RBCtransfusion.Patientswhoreceived P(cid:3).001)andhematocrit(38.3%[95%
strategygroupsinmeanlactatelevels RBCtransfusionswereolder(mean,61 CI, 37.8%-38.8%] vs 42.2% [95% CI,
(27.03mg/dL[95%CI,26.13-27.93]vs years [95% CI, 59.6-62.4] vs 58 years 41.6%-42.9%],P(cid:3).001),longercardio-
pulmonarybypassduration(96.4min-
utes[95%CI,93.0-99.9]vs90.5min-
Table.BaselineCharacteristicsofStudyPatients utes[95%CI,86.5-94.5],P=.03),and
No.(%) higherlactatevaluesattheendofsur-
gery (43.24 mg/dL [95% CI, 40.54-
LiberalStrategy RestrictiveStrategy P
Variable (n=253) (n=249) Value 45.95]vs36.94mg/dL[95%CI,33.33-
Age,mean(SD),y 60.7(12.5) 58.6(12.5) .06 39.64],P=.003),andmorereceivedfresh
Men 161(64) 149(60) .38 frozenplasmaintraoperatively(24%vs
Bodymassindex,mean(SD)a 26.1(4.3) 26.3(4.4) .65
11%,P(cid:3).001)(eTable3).Afteradmis-
Comorbidconditions siontotheICU,patientswhoreceived
Hypertension 201(79) 192(77) .53 an RBC transfusion had higher Acute
Diabetes 79(31) 86(35) .45 PhysiologyandChronicHealthEvalu-
Dyslipidemia 139(55) 147(60) .33 ationIIscores(9[95%CI,8.5-9.5]vs7.4
Renaldisease 26(11) 26(11) .50 [95%CI,6.9-7.9],P(cid:3).001)andSimpli-
Smoking 34(14) 38(16) .74 fied Acute Physiology Score II values
COPD 6(2) 8(3) .55 (21.7[95%CI,20.5-22.9]vs18.6[95%
Unstableangina 79(31) 76(31) .87 CI,17.3-20.0],P(cid:3).001)comparedwith
Previousmyocardialinfarction 86(34) 89(36) .61 those who did not. Patients who re-
Heartfailure,NYHAclassification ceived RBC transfusions had longer
I 8(6) 8(7)
lengthsofICUstay(median,4[IQR,2-7]
II 42(34) 48(41)
.50
daysvs3[IQR,2-4]days;P(cid:3).001)and
III 65(52) 49(42)
hospital stay (median, 10 [IQR, 7-17]
IV 10(8) 11(10) days vs 8 [IQR, 7-12] days, P(cid:3).001)
LVEF,%
comparedwithnontransfusedpatients.
30-39 32(13) 37(15)
Inthemultivariatemodel,previous
40-59 76(30) 75(30) .75
(cid:2)60 145(57) 137(55) cardiacsurgery(oddsratio[OR],8.92
[95%CI,1.05-76.1];P=.04),femalesex
Reoperation 11(4) 13(5) .65
(OR,1.81[95%CI,1.03-3.18];P=.04),
EuroSCORE,median(IQR) 5(3-6) 4(3-7) .07
finallactatelevels(OR,1.02[95%CI,
Preoperativelaboratoryvalues,mean(SD)
Hemoglobin,g/dL 13.1(1.6) 13.4(1.8) .18 1.01-1.04]; P=.001), duration of by-
Hematocrit,% 39.5(4.3) 39.9(5.2) .65 pass (OR, 1.01 [95% CI, 1.00-1.02];
Prothrombintime,s 11.3(1.1) 11.3(2.2) .54 P=.03),andbaselinehemoglobinlevel
Plateletcount,(cid:4)103/µL 222(67) 225(66) .83 (OR, 0.51 [95% CI, 0.43-0.62];
Creatininelevel,mg/dL 1.12(0.4) 1.12(0.3) .99
P(cid:3).001)werepredictiveofRBCtrans-
Leukocytecount/µL 7600(2100) 7700(2000) .56 fusion(eTable4).
Preoperativedrugexposure Todeterminetheeffectofthenum-
Aspirin 103(41) 94(38) .52 beroftransfusedRBCunitsonclinical
Heparin 3(1) 2(1) (cid:6).99 complications, we performed a mul-
Abbreviations:COPD,chronicobstructivepulmonarydisease;EuroSCORE,EuropeanSystemforCardiacOperativeRisk tiple logistic regression analysis. The
Evaluation;IQR,interquartilerange;LVEF,leftventricularejectionfraction;NYHA,NewYorkHeartAssociation.
SIconversionfactor:Toconvertcreatininevaluestoµmol/L,multiplyby88.4. numberoftransfusedRBCunitswasan
aCalculatedasweightinkilogramsdividedbyheightinmeterssquared.
independent risk factor for the occur-
1564 JAMA,October13,2010—Vol304,No.14(Reprinted) ©2010AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a SUNY Binghamton User on 05/13/2015
renceofseveralclinicalcomplications.
Foreachtransfusedunit,theriskofoc-
currenceincreasedforrespiratorycom-
plications (OR, 1.27 [95% CI, 1.12-
1.45];P(cid:3).001),cardiaccomplications
(OR,1.28[95%CI,1.14-1.45];P(cid:3).001),
renalcomplications(OR,1.26[95%CI,
1.08-1.46];P=.004),infectiouscompli-
cations(OR,1.20[95%CI,1.05-1.37];
P=.007),andthecompositeendpoint
(OR,1.25[95%CI,1.09-1.42];P(cid:3).001)
(eTable5).
Transfusionof5ormoreRBCunits
was associated with higher mortality
(FIGURE 4). In a multivariate Cox re-
gressionanalysisthatincludedageand
sex,typeofsurgery,leftventricularejec-
tion fraction, previous cardiac sur- gery,initialandfinaloperativehemo-
globin level and hematocrit, lactate
level,andSCVO2,thenumberoftrans-
fusedRBCunitswasindependentlyas-
sociatedwithanincreasedriskofdeath
at30daysintheentirepopulation(haz-
ardratio,1.2[95%CI,1.1-1.4];P=.002) talityratesandratesofinpatientcom-
Figure3.Kaplan-MeierEstimatesof30-Day
(eTable6). plicationsbetweenour2groups,there
SurvivalbyTransfusionStrategy
wasatrendtowardanincreasedinci-
COMMENT
denceofcardiogenicshockinpatients 8
Toourknowledge,thisisthefirstpro- treatedusingtherestrictivecompared 7
spective,controlled,randomizedclini- withtheliberalstrategy. 6 Restrictive strategy
5
caltrialtocomparealiberalwithare- Inarandomizedcontrolledclinical
4
strictivetransfusionstrategyinpatients trialof838criticallyillpatients(notin- 3
Liberal strategy
undergoing cardiac surgery. Our data cluding patients undergoing cardiac 2
suggestthatarestrictivetransfusionstrat- surgery),He´bertetalshowedthatare- 1
Log-rank P = .99
egytargetingahematocritof24%isas strictivestrategyofredbloodcelltrans- 0
0 3 6 9 12 15 18 21 24 27 30
safeasaliberalstrategytargetingahe- fusionwasaseffectiveasandpossibly Time, d
No. at risk
matocritof30%,withrespecttoacom- superiortoaliberaltransfusionstrat-
Restrictive 249 244 238 236 235 234
positeendpointof30-daymortalityand egy.13However,incardiacsurgery,there Liberal 253 248 247 245 245 242
inpatientclinicalcomplications.More- have been no similar large random-
over,regardlessofthetreatmentstrat- izedcontrolledtrials.Twosmallstud-
egy,thenumberoftransfusedRBCunits iesinpatientsundergoingCABGsur-
wasanindependentriskfactorforworse gerysuggestedthatdifferenttransfusion
outcomes,includingmortality. strategies gave similar outcomes29,30;
Patients in this study experienced however, the small numbers of pa- increasedcostsandadverseeffectsasso-
slightlyhigherratesofseriouscompli- tientsinthosestudiesdidnotallowfor ciatedwithRBCtransfusion.32,33Thesead-
cations than those in other stud- definitive conclusions to be drawn. verseeffectsincludeacutehemolyticand
ies,27,28 likely because our population Guidelines from the Society of Tho- nonhemolyticreactions,transmissionof
was a higher-risk group, with a me- racicSurgeonsandSocietyofCardio- viralandbacterialdiseases,transfusion-
dianEuroScoreof4to5andwithsome vascular Anesthesiologists emphasize relatedacutelunginjury,andtransfusion-
patientsundergoingvalvesurgeryalone thelackofevidenceontransfusiontrig- associatedcirculatoryoverload.Immu-
orcombinedwithCABGsurgery.Inad- gersaftercardiacsurgery.31 nosuppressionhasalsobeenassociated
dition,ourhospitalisareferralcenter Therationaleforimplementingare- with transfusion and may explain the
forcardiacsurgery,andsomepatients strictivetransfusionstrategyisbasedon higherriskofinfectionandrecurrenceof
wereseverelyill.Althoughtherewere manystudiesthathaveshownalackof neoplasticdiseasesobservedintransfused
no significant differences in the mor- benefitand,atthesametime,substantially patients.34,35Evidencefromretrospective
%
,ytilatroM
fo
ytilibaborP
Figure2.MeanHemoglobinLevelsDuringtheStudyAccordingtoTransfusionStrategy
16
15
14
13
12
11
10
9
8
7
Preop I mn etr dia ao tp e Postop 1 2 3 Days After IC4 U Admission5 6 7
m
I
Timezerowasjustafterrandomization(12hoursbe-
foresurgery).Hazardratio,1.28(95%confidencein-
terval,0.60-2.73)(P=.99)forrestrictivestrategyvs
liberalstrategy.
Ld/g
,nibolgomeH
naeM
TRANSFUSIONREQUIREMENTSAFTERCARDIACSURGERY
Liberal strategy
Restrictive strategy
P(cid:3).05betweenthegroupsatallpointsfollowingpreop.Errorbarsindicate95%confidenceintervals.ICU
indicatesintensivecareunit.
©2010AmericanMedicalAssociation.Allrightsreserved. (Reprinted)JAMA,October13,2010—Vol304,No.14 1565
Downloaded From: http://jama.jamanetwork.com/ by a SUNY Binghamton User on 05/13/2015
anemiaandmyocardialinfarctionseem fusionstrategy,transfusingevenasingle
Figure4.Kaplan-MeierEstimatesof30-Day
tosuggestthattransfusionmaybeben- RBCunitwasassociatedwithasignifi-
SurvivalBasedonNumberofRedBloodCell
(RBC)UnitsTransfused eficial(ORformortality,0.42[95%CI, cantly increased risk of serious post-
0.20-0.89]),40particularlyforpatients operativemorbidityandmortality.RBC
olderthan65years(ORformortality, transfusionwasindependentlyassoci-
0.69 [95% CI, 0.53-0.89]; hematocrit ated with a 1.2-fold increased risk of
Log-rank P = .03
20 range,30-33).41Inourstudy,patients death at 30 days for each unit trans-
18 withcardiovasculardiseasedidnothave fused.Thesefindingssuggestthatthe
16
14 adverse outcomes when a hematocrit primarystrategyinpatientsundergo-
12 threshold of 24% was used. This ap- ingcardiacsurgeryshouldbetoavoid
10
8 parentdiscrepancymaybetheresultof giving RBC transfusion solely to cor-
6 confoundingorbecausethehemoglo- rect low hemoglobin levels. The in-
4
2 binconcentrationsofourpatientsdur- creasedriskofmortalityrelatedtothe
0 ingthestudywerenotlessthan9g/dL. numberoftransfusedRBCunitssup-
0 3 6 9 12 15 18 21 24 27 30
Time, d Sixty-three percent of our study portsarestrictivetherapyincardiacsur-
No. at risk population received an RBC transfu- gery.Inaddition,clinicianscaringfor
RBC units
0 186 184 183 182 182 181 sion. A similar rate was reported in a patientsaftercardiacsurgeryshouldad-
1-2 191 187 184 182 182 179
3-4 84 83 82 82 81 80 retrospectivestudyof8724patientspre- ministeronly1RBCunitatatime,be-
5-6 25 24 24 22 22 21 sentingalowernumberofriskfactors causethismayresultinlessexposure
>6 16 15 13 13 13 12
fortransfusion,suchasolderage,heart torisksbutsimilarbenefits.
failure, on-pump surgery, and valve Limitationsofourstudyincludethat
procedures.40Reoperation,femalesex, itwasperformedinasinglereferralcen-
highfinallactatelevelintheoperating ter for cardiac surgery, which could
room, long bypass duration, and low compromisethegeneralizabilityofour
baseline hemoglobin level were inde- findings.Anotherlimitationisthelack
pendently associated with transfu- ofbloodleukodepletioninourstudy,
sion.Theseobservationsaresimilarto whichreflectscurrentpracticeinBra-
studieshaspointedtoworseearly,mid- those reported in previous retrospec- zilbutagaincouldlimitgeneralizabil-
term,andlong-termoutcomesrelatedto tivestudies.42-44 ity.Somestudies,46,47butnotall,48have
transfusioninpatientsundergoingcar- Asexpected,therestrictive-strategy suggested better outcomes in criti-
diacsurgery.36,37Inaretrospectiveanaly- patientsreceivedfewerRBCunitsthan cally ill patients who receive transfu-
sisof11963patientswhounderwentiso- theliberal-strategypatientsand,con- sionsofleukodepletedRBCs.Thepo-
latedCABGsurgery,Kochetalshowed sequently, had lower mean hemoglo- tentialhigherriskassociatedwithuse
thatperioperativeRBCtransfusionwas bin levels during the study. Interest- ofnonleukodepletedbloodinourstudy
associated with a dose-dependent in- ingly, this did not result in a higher may be compensated for by the rela-
creasedriskofpostoperativecardiaccom- incidenceofclinicalcomplications.Pre- tivelyyoungageoftheRBCs,withame-
plications,seriousinfection,renalfailure, sumablythisoccurredbecausethere- dianofonly3daysofstorageinboth
neurologiccomplications,overallmorbid- strictive strategy did not result in re- groups,theresultofroutineactivese-
ity,prolongedventilatorsupport,andin- ducedoxygenavailabilitytothecells. lectionoffreshblood(storedlessthan
hospitalmortality.38Inasimilarretrospec- Thisissupportedbythelackofdiffer- 10days)forpatientsundergoingcar-
tivestudy,Murphyetal39showedthatRBC ence in lactate levels between the 2 diacsurgeryatourinstitution.Inone
transfusionwasstronglyassociatedwith groupsduringthestudyperiod. study,transfusionswithbloodstored
infectionandwithpostoperativeischemic In our study, independent of the formorethan14dayswereassociated
morbidity,hospitalstay,increasedearly treatment strategy, patients who re- withasignificantincreaseinmorbid-
andlatemortality,andhospitalcosts. ceivedanRBCtransfusionhadhigher ityandmortalityinpatientsundergo-
However, there has been concern ratesofcomplicationsaftersurgery,in- ingcardiacsurgery.49
abouttheadverseeffectsofanemiain cluding 30-day mortality. The num- Inconclusion,usinganoninferior-
patients with cardiovascular dis- beroftransfusedRBCunitswasapre- itymarginof−8%amongpatientsun-
ease.4,5Oneretrospectivecohortstudy dictivefactorfor30-daymortality.As dergoingelectivecardiacsurgery,the
of1958surgicalpatientsreportedthat already suggested by Koch et al38 for useofarestrictiveperioperativetrans-
increasedseverityofanemiawasasso- adultcardiacproceduresandbyGauvin fusionstrategycomparedwithamore
ciated with a disproportionate in- etal45forpediatriccardiacoperations, liberalstrategyresultedinnoninferior
crease in mortality rates among pa- we showed that the higher the num- ratesofthecombinedoutcomeof30-
tients with cardiovascular disease.4 beroftransfusedRBCunits,thehigher dayall-causemortalityandseveremor-
Moreover,somestudiesinpatientswith themortality.Regardlessofthetrans- bidity.
%
,ytilatroM
fo
ytilibaborP
TRANSFUSIONREQUIREMENTSAFTERCARDIACSURGERY
RBC units
0
1-2
3-4
5-6
>6
Timezerowasjustafterrandomization(12hoursbe-
foresurgery).With0RBCunitsasthereferencecat-
egory,thehazardratiowas2.97(95%confidencein-
terval[CI],0.96-9.21)(P=.06)for1to2RBCunits;2.78
(95%CI,0.75-10.35)(P=.13)for3to4units;5.82
(95%CI,1.30-26.02)(P=.02)for5to6units;and9.70
(95%CI,2.17-43.34)(P=.003)formorethan6units.
1566 JAMA,October13,2010—Vol304,No.14(Reprinted) ©2010AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a SUNY Binghamton User on 05/13/2015
TRANSFUSIONREQUIREMENTSAFTERCARDIACSURGERY
AuthorContributions:DrHajjarhadfullaccesstoall 13. He´bertPC,WellsG,BlajchmanMA,etal;Trans- etal.Limitationsofbloodconservation.JThoracCar-
ofthedatainthestudyandtakesresponsibilityfor fusionRequirementsinCriticalCareInvestigators,Ca- diovascSurg.1984;88(1):26-38.
theintegrityofthedataandtheaccuracyofthedata nadianCriticalCareTrialsGroup.Amulticenter,ran- 31. FerrarisVA,FerrarisSP,SahaSP,etal;Societyof
analysis. domized, controlled clinical trial of transfusion ThoracicSurgeonsBloodConservationGuidelineTask
Studyconceptanddesign:Hajjar,Vincent,Galas,Auler. requirementsincriticalcare.NEnglJMed.1999; Force;SocietyofCardiovascularAnesthesiologistsSpe-
Acquisitionofdata:Hajjar,Galas,Nakamura,Silva, 340(6):409-417. cialTaskForceonBloodTransfusion.Perioperative
Santos,Sierra,Lopes,Roquim,Lea˜o,Dallan. 14. vonHeymannC,SanderM,FoerA,etal.The bloodtransfusionandbloodconservationincardiac
Analysisandinterpretationofdata:Hajjar,Vincent, impactofanhematocritof20%duringnormother- surgery.AnnThoracSurg.2007;83(5)(suppl):S27-
Galas,Fukushima,KalilFilho,Mauad,Sundin,Almeida, miccardiopulmonarybypassforelectivelowrisk S86.
Pomerantzeff,Jatene,Stolf,Auler. coronaryarterybypassgraftsurgeryonoxygende- 32. ScottBH,SeifertFC,GrimsonR.Bloodtransfu-
Draftingofthemanuscript:Hajjar,Vincent,Nakamura, liveryandclinicaloutcome.CritCare.2006;10 sionisassociatedwithincreasedresourceutilisation,
Almeida. (2):R58. morbidityandmortalityincardiacsurgery.AnnCard
Criticalrevisionofthemanuscriptforimportantin- 15. BergerK,SanderM,SpiesCD,etal.Profoundhae- Anaesth.2008;11(1):15-19.
tellectualcontent:Vincent,Galas,Silva,Santos, modilutionduringnormothermiccardiopulmonaryby- 33. SpiessBD.Bloodtransfusion:thesilentepidemic.
Fukushima,KalilFilho,Sierra,Lopes,Mauad,Roquim, passinfluencesneithergastrointestinalpermeabilitynor AnnThoracSurg.2001;72(5):S1832-S1837.
Sundin,Lea˜o,Pomerantzeff,Dallan,Jatene,Stolf,Auler. cytokinereleaseincoronaryarterybypassgraftsurgery. 34. DespotisGJ,ZhangL,LublinDM.Transfusionrisks
Statisticalanalysis:Fukushima. BrJAnaesth.2009;103(4):511-517. andtransfusion-relatedpro-inflammatoryresponses.
Administrative, technical, or material support: 16. NashefSA,RoquesF,MichelP,etal.European HematolOncolClinNorthAm.2007;21(1):147-
Nakamura,Silva,Santos,KalilFilho,Sierra,Lopes, System for Cardiac Operative Risk Evaluation 161.
Roquim,Sundin,Lea˜o,Almeida,Pomerantzeff,Dallan, (euroSCORE).EurJCardiothoracSurg.1999;16 35. ZachariasA,HabibRH.Factorspredisposingto
Jatene,Stolf,Auler. (1):9-13. mediansternotomycomplications:deepvssuperfi-
Studysupervision:Hajjar,Vincent,Galas,Mauad, 17. LeGallJR,LemeshowS,SaulnierF.AnewSim- cialinfection.Chest.1996;110(5):1173-1178.
Auler. plifiedAcutePhysiologyScore(SAPSII)basedona 36. KuduvalliM,OoAY,NewallN,etal.Effectofperi-
FinancialDisclosures:Nonereported. European/NorthAmericanmulticenterstudy.JAMA. operativeredbloodcelltransfusionon30-dayand
Online-OnlyMaterial:eTables1through6and 1993;270(24):2957-2963. 1-yearmortalityfollowingcoronaryarterybypass
eFigures1and2areavailableathttp://www.jama 18. KnausWA,DraperEA,WagnerDP,Zimmerman surgery.EurJCardiothoracSurg.2005;27(4):592-
.com. JE.APACHEII:aseverityofdiseaseclassificationsystem. 598.
CritCareMed.1985;13(10):818-829. 37. KochCG,LiL,DuncanAI,etal.Transfusionin
19. BernardGR,ArtigasA,BrighamKL,etal.The coronaryarterybypassgraftingisassociatedwithre-
REFERENCES American-EuropeanConsensusConferenceonARDS: ducedlong-termsurvival.AnnThoracSurg.2006;
definitions,mechanisms,relevantoutcomes,andclini- 81(5):1650-1657.
1. StoverEP,SiegelLC,ParksR,etal;Institutionsof caltrialcoordination.AmJRespirCritCareMed.1994; 38. KochCG,LiL,DuncanAI,etal.Morbidityand
theMulticenterStudyofPerioperativeIschemiaRe- 149(3,pt1):818-824. mortalityriskassociatedwithredbloodcellandblood-
searchGroup.Variabilityintransfusionpracticefor 20. CroceMA.Postoperativepneumonia.AmSurg. componenttransfusioninisolatedcoronaryarteryby-
coronaryarterybypasssurgerypersistsdespitena- 2000;66(2):133-137. passgrafting.CritCareMed.2006;34(6):1608-
tionalconsensusguidelines:a24-institutionstudy. 21. Masse´L,AntonacciM.Lowcardiacoutputsyn- 1616.
Anesthesiology.1998;88(2):327-333. drome:identificationandmanagement.CritCareNurs 39. MurphyGJ,ReevesBC,RogersCA,etal.In-
2. RogersMA,BlumbergN,SaintS,etal.Hospital ClinNorthAm.2005;17(4):375-383. creasedmortality,postoperativemorbidity,andcost
variationintransfusionandinfectionaftercardiac 22. ThygesenK,AlpertJS,WhiteHD;JointESC/ afterredbloodcelltransfusioninpatientshavingcar-
surgery.BMCMed.2009;7:37. ACCF/AHA/WHFTaskForcefortheRedefinitionof diac surgery. Circulation. 2007;116(22):2544-
3. Snyder-RamosSA,MöhnleP,WengYS,etal;In- MyocardialInfarction.Universaldefinitionofmyo- 2552.
vestigatorsoftheMulticenterStudyofPerioperative cardialinfarction.JAmCollCardiol.2007;50(22): 40. SabatineMS,MorrowDA,GiuglianoRP,etal.As-
Ischemia;MCSPIResearchGroup.Theongoingvari- 2173-2195. sociationofhemoglobinlevelswithclinicaloutcomes
abilityinbloodtransfusionpracticesincardiacsurgery. 23. HaaseM,BellomoR,MatalanisG,CalzavaccaP, inacutecoronarysyndromes.Circulation.2005;
Transfusion.2008;48(7):1284-1299. DragunD,Haase-FielitzA.Acomparisonofthe 111(16):2042-2049.
4. CarsonJL,DuffA,PosesRM,etal.Effectofanae- RIFLEandAcuteKidneyInjuryNetworkclassifica- 41. WuWC,RathoreSS,WangY,etal.Bloodtrans-
miaandcardiovasculardiseaseonsurgicalmortality tionsforcardiacsurgery–associatedacutekidney fusioninelderlypatientswithacutemyocardial
and morbidity. Lancet. 1996;348(9034):1055- injury. J Thorac Cardiovasc Surg. 2009;138(6): infarction. N Engl J Med. 2001;345(17):1230-
1060. 1370-1376. 1236.
5. DeFoeGR,RossCS,OlmsteadEM,etal;North- 24. KlugkistM,Sedemund-AdibB,SchmidtkeC,etal. 42. KarkoutiK,CohenMM,McCluskeySA,SherGD.
ernNewEnglandCardiovascularDiseaseStudyGroup. ConfusionAssessmentMethodfortheIntensiveCare Amultivariablemodelforpredictingtheneedforblood
Lowesthematocritonbypassandadverseoutcomes Unit(CAM-ICU):diagnosisofpostoperativedelirium transfusioninpatientsundergoingfirst-timeelective
associatedwithcoronaryarterybypassgrafting.Ann incardiacsurgery[inGerman].Anaesthesist.2008; coronarybypassgraftsurgery.Transfusion.2001;
ThoracSurg.2001;71(3):769-776. 57(5):464-474. 41(10):1193-1203.
6. MarikPE,CorwinHL.Efficacyofredbloodcelltrans- 25. Levy MM, Fink MP, Marshall JC, et al; 43. ScottBH,SeifertFC,GlassPS,GrimsonR.Blood
fusioninthecriticallyill:asystematicreviewofthe SCCM/ESICM/ACCP/ATS/SIS.2001SCCM/ESICM/ useinpatientsundergoingcoronaryarterybypass
literature.CritCareMed.2008;36(9):2667-2674. ACCP/ATS/SIS International Sepsis Definitions surgery.AnesthAnalg.2003;97(4):958-963.
7. Leal-NovalSR,Rinco´n-FerrariMD,Garcı´a-Curiel Conference. Crit Care Med. 2003;31(4):1250- 44. vanStratenAH,KatsS,BekkerMW,etal.Risk
A,etal.Transfusionofbloodcomponentsandpost- 1256. factorsforredbloodcelltransfusionaftercoronaryar-
operativeinfectioninpatientsundergoingcardiac 26. DespotisGJ,SkubasNJ,GoodnoughLT.Opti- terybypassgraftsurgery.JCardiothoracVascAnesth.
surgery.Chest.2001;119(5):1461-1468. malmanagementofbleedingandtransfusioninpa- 2010;24(3):413-417.
8. EngorenMC,HabibRH,ZachariasA,etal.Effect tientsundergoingcardiacsurgery.SeminThoracCar- 45. GauvinF,ChampagneMA,RobillardP,etal.Long-
ofbloodtransfusiononlong-termsurvivalaftercar- diovascSurg.1999;11(2):84-104. termsurvivalrateofpediatricpatientsafterblood
diacoperation.AnnThoracSurg.2002;74(4):1180- 27. WhitsonBA,HuddlestonSJ,SavikK,Shumway transfusion.Transfusion.2008;48(5):801-808.
1186. SJ.Riskofadverseoutcomesassociatedwithblood 46. TangAT,AlexiouC,HsuJ,etal.Leukodepletion
9. ReevesBC,MurphyGJ.Increasedmortality,mor- transfusionaftercardiacsurgerydependsonthe reducesrenalinjuryincoronaryrevascularization.Ann
bidity,andcostassociatedwithredbloodcelltrans- amountoftransfusion.JSurgRes.2010;158(1): ThoracSurg.2002;74(2):372-377.
fusionaftercardiacsurgery.CurrOpinCardiol.2008; 20-27. 47. BilginYM,vandeWateringLM,EijsmanL,etal.
23(6):607-612. 28. SurgenorSD,KramerRS,OlmsteadEM,etal; Double-blind,randomizedcontrolledtrialontheeffect
10. MadjdpourC,SpahnDR,WeiskopfRB.Anemia NorthernNewEnglandCardiovascularDiseaseStudy ofleukocyte-depletederythrocytetransfusionsincar-
andperioperativeredbloodcelltransfusion.CritCare Group.Theassociationofperioperativeredbloodcell diac valve surgery. Circulation. 2004;109(22):
Med.2006;34(5)(suppl):S102-S108. transfusionsanddecreasedlong-termsurvivalaftercar- 2755-2760.
11. VincentJL,PiagnerelliM.Transfusioninthein- diacsurgery.AnesthAnalg.2009;108(6):1741- 48. EfstathiouA,VlachveisM,TsonisG,etal.Does
tensivecareunit.CritCareMed.2006;34(5)(suppl): 1746. leukodepletionduringelectivecardiacsurgeryreally
S96-S101. 29. JohnsonRG,ThurerRL,KruskallMS,etal.Com- influencetheoverallclinicaloutcome?JCardiovasc
12. BraceyAW,RadovancevicR,RiggsSA,etal.Low- parisonoftwotransfusionstrategiesafterelectiveop- Surg(Torino).2003;44(2):197-204.
eringthehemoglobinthresholdfortransfusionincoro- erationsformyocardialrevascularization.JThoracCar- 49. KochCG,LiL,SesslerDI,etal.Durationofred-
naryarterybypassprocedures:effectonpatient diovascSurg.1992;104(2):307-314. cellstorageandcomplicationsaftercardiacsurgery.
outcome.Transfusion.1999;39(10):1070-1077. 30. WeiselRD,CharlesworthDC,MickleboroughLL, NEnglJMed.2008;358(12):1229-1239.
©2010AmericanMedicalAssociation.Allrightsreserved. (Reprinted)JAMA,October13,2010—Vol304,No.14 1567
Downloaded From: http://jama.jamanetwork.com/ by a SUNY Binghamton User on 05/13/2015
